White House and congressional allies continue to push for filibuster against majority disapproval of deal


Reports on Thursday continued to indicate that the Obama administration and its congressional allies are pushing for a filibuster of the resolution of disapproval regarding the Iran deal. A senior White House official indicated to The Jerusalem Post that the White House would not oppose efforts made by Democrats in Congress to block a vote. Roll Call reported, “The White House is not explicitly campaigning for a filibuster but it is privately understood to badly want one in order to prevent the Republican-controlled Congress from voting down the deal and requiring the president to use his veto.” Such an occurrence would, the article continued, “send a confusing signal to international audiences about where the United States stands on the agreement and so is something the Obama administration and its proxies are eager to avoid.” The Wall Street Journal’s editorial board criticized a potential filibuster, saying that it would be “using a procedural dodge to avoid voting on the merits of so consequential a deal.”

On Wednesday, Chris Coons (D-Del.) told CNN that “it would be really regrettable if we didn't ultimately go to the floor and cast our votes for or against this deal." When the Iran Nuclear Agreement Review Act, which calls for congressional review of the Iran deal, was signed in May, President Obama “was pleased that Congress did pass this piece of legislation” but a filibuster would go against the spirit of the legislation. According to a recent Quinnipiac University poll, a majority of American voters oppose the deal, and preventing Congress from voting on it would deny representatives of the American public the ability to represent their constituents’ positions.


Hundreds of Floridians protested the nuclear deal with Iran outside a community center where Vice President Joe Biden arrived to deliver a speech in favor of the agreement, CBS Miami reported today.

Carrying signs and waving banners, protestors set up camp near the David Posnack Jewish Community Center in Davie Thursday morning where Vice President Joe Biden met with Jewish community leaders to discuss the administration’s nuclear deal reached with Iran.


The vice president’s limo passed several hundred anti-Iran deal protestors gathered on the street across from the center. One was waving a large Israeli flag. Several waved signs which read “Stop Iran Deal”; “Nuke the Deal Before They Nuke Us”‎ and “We need a better dea‎l”

According to the Sun Sentinel, nearly 800 people had attended the protest.

A Quinnipiac University poll last month showed that Florida voters opposed the nuclear deal by a 61% to 25% margin, while a poll released last week by Secure America Now found that 82% of Americans don’t want Iran to receive sanctions relief without congressional approval.

Despite this widespread public opposition, which is reflected in the position of a bipartisan majority in Congress, there is a movement to recruit enough senators to filibuster the vote over the nuclear agreement. Ben Cohen, senior editor of The Tower, wrote yesterday that a filibuster would “mean that critical reservations about the deal, even among its supporters, will not be articulated in Congress.” Sen. Chris Coons (D – Del.), who earlier this week announced his support of deal, rejected the idea of a filibuster, saying, “I think it would be really regrettable if we didn’t ultimately go to the floor and cast our votes for or against this deal.” (via TheTower.org)


A mega acquisition deal worth roughly $929 million of Israeli replacement heart valve maker Valtech Cardio by HeartWare International has Israel’s startup sector buzzing with excitement. The US-based heart technology company announced late yesterday that it has entered into a definitive agreement to acquire the privately held Or Yehuda company, which employs just 40 people, and specializes in the development of devices for mitral and tricuspid valve repair and replacement. It is the biggest buy-out of an Israeli medical device company ever, and one of the biggest deals in any industry in Israel. It comes in the wake of a bumper year when in one week alone inJanuary acquisitions of companies including Annapurna Labs, Red Bend Software, CloudOn  and others reached $900 million. “By joining HeartWare, we can more quickly and fully realize the potential of our pipeline technologies and further influence the underpenetrated markets that we serve,” said Amir Gross, founder and CEO of Valtech. Terms of the deal will see Valtech shareholders receive an up-front consideration of 4.4 million shares of HeartWare common stock; 800,000 shares of HeartWare common stock, contingent upon CE Mark approval for Cardioband; and 700,000 shares of HeartWare common stock upon the earlier of first-in-man implants for either Cardioband tricuspid or CardioValve. The deal is said to be worth at least $929 million. The buy-out is subject to regulatory approvals as well as HeartWare stockholder and Valtech shareholder approvals, the Massachusetts company said.  The deal is expected to be closed later this year. (via Israel21c)


Be the first to comment

Please check your e-mail for a link to activate your account.